The Possible Impact of Digital Twins on Market Access Through Clinical Trials

Key Takeaways from The Possible Impact of Digital Twins on Market Access Through Clinical Trials

1. Introduction to Digital Twins: Digital twins, initially developed in the manufacturing sector, are now being applied in healthcare to create virtual replicas of patients, enhancing clinical trial processes and impacting market access for new treatments.
2. Enhanced Clinical Trials: Digital twins in healthcare involve creating precise virtual models of patients using real-time data, which can simulate scenarios, predict outcomes, and personalize treatment plans, revolutionizing traditional clinical trial methods.
3. Improved Patient Recruitment and Retention: By simulating patient responses to treatments, digital twins help identify the most suitable candidates for trials, reducing recruitment time and cost, and improving patient adherence and retention rates.
4. Facilitating Regulatory Approval: Digital twins provide robust and comprehensive evidence of treatment efficacy and safety, addressing regulatory concerns effectively, accelerating the approval process, and improving market access for new therapies.
5. Efficient Trial Design: Digital twins enable virtual simulations of clinical trials, identifying potential issues and optimizing trial designs before physical trials begin, reducing the need for extensive physical trials and associated costs.
6. Predictive Capabilities: With advanced predictive modeling, digital twins forecast patient responses, identify potential adverse effects, and suggest optimal dosing regimens, leading to more successful and cost-effective trials.
7. Real-Time Monitoring and Data Integration: Digital twins continuously analyze data from various sources like EHRs, wearable devices, and genetic information, providing comprehensive patient monitoring, early detection of issues, and ensuring accurate trial outcomes.
8. Cost and Time Savings: By enabling adaptive trial designs and real-time adjustments based on emerging data, digital twins streamline trial processes, reducing costs and time required for new therapy development and approval.
9. Ethical and Practical Considerations: The use of digital twins involves addressing data privacy and security, ensuring interoperability with existing systems, obtaining informed consent, mitigating biases, and managing costs and resources effectively.
10. Impact on Personalized Medicine: Digital twins advance personalized medicine by tailoring therapies to individual patient’s genetic makeup and health history, improving treatment effectiveness, patient outcomes, and overall healthcare delivery.

Please look at the Market Access & HEOR Resource category for more articles.

What is Digital Twins in Clinical Trials?

Digital twins, a cutting-edge technology originally developed in the manufacturing sector, have found their way into the healthcare industry, offering promising advancements in clinical trials. By creating virtual replicas of patients, digital twins can significantly enhance the clinical trial process, ultimately impacting market access for new treatments.

Digital twins in healthcare involve the creation of precise virtual models of individual patients using real-time data. These models can simulate different scenarios, predict outcomes, and provide personalized treatment plans. The integration of digital twins into clinical trials can revolutionize the traditional methods of testing new drugs and therapies by providing a more efficient, cost-effective, and accurate approach.

One of the significant advantages of digital twins is their ability to enhance patient recruitment and retention in clinical trials. By simulating patient responses to treatments, researchers can identify the most suitable candidates for trials, reducing the time and cost associated with recruitment. Moreover, digital twins can help in monitoring patient adherence and response to treatment, leading to better retention rates and more reliable data.

Furthermore, digital twins can facilitate the regulatory approval process by providing robust and comprehensive evidence of a treatment’s efficacy and safety. The ability to simulate long-term outcomes and potential adverse effects can address regulatory concerns more effectively, potentially accelerating the approval process and improving market access for new therapies.

In conclusion, the adoption of digital twin technology in clinical trials represents a transformative advancement in the healthcare industry. By improving the efficiency, accuracy, and cost-effectiveness of clinical trials, digital twins have the potential to significantly impact market access for new treatments, ultimately benefiting patients and healthcare providers alike.

Digital Twins for Revolutionizing Clinical Trials

In the rapidly evolving landscape of clinical trials, digital twin technology stands out as a groundbreaking advancement, offering enhanced patient monitoring and personalized medicine. By providing continuous, real-time insights into each patient’s health status, digital twins enable healthcare providers to customize treatments more effectively. This individualized approach not only improves patient outcomes but also provides compelling evidence for the efficacy of new therapies, thus facilitating quicker market access.

Enhanced Patient Monitoring and Personalized Medicine

Digital twins provide continuous monitoring and real-time data analysis, allowing for a more detailed understanding of each patient’s health status. This individualized approach enables the customization of treatments, improving patient outcomes and demonstrating the efficacy of new therapies more convincingly.

Digital twin technology allows for the aggregation and analysis of vast amounts of data from various sources such as electronic health records (EHRs), wearable devices, and genetic information. By integrating this data into a cohesive model, healthcare providers can gain insights into a patient’s health trajectory, predict potential complications, and intervene proactively. This level of monitoring surpasses traditional methods, which often rely on periodic check-ups and self-reported information.

Moreover, the real-time data analysis provided by digital twins ensures that any deviations from expected health parameters are quickly identified. This prompt detection allows for immediate adjustments to treatment plans, enhancing the responsiveness of healthcare interventions. For instance, if a digital twin detects early signs of adverse reactions to a medication, clinicians can swiftly modify the dosage or switch to an alternative therapy, thereby minimizing risks and improving patient safety.

Personalized medicine is further advanced by the predictive capabilities of digital twins. These virtual models can simulate how individual patients might respond to different treatment options based on their unique genetic makeup and health history. This predictive modeling enables healthcare providers to tailor therapies that are most likely to be effective for each patient, reducing the trial-and-error approach often associated with traditional treatment methods.

In clinical trials, the use of digital twins can provide more compelling evidence of a therapy’s efficacy. By demonstrating how treatments perform across a diverse set of virtual patients, researchers can gather robust data on potential outcomes and side effects. This comprehensive evidence can support more convincing arguments for the approval and adoption of new therapies.

In summary, digital twins enhance patient monitoring and personalized medicine by providing continuous, real-time insights into individual health statuses and enabling the customization of treatments. This technology not only improves patient outcomes but also strengthens the evidence supporting new therapies, facilitating their path to market access.

Simulation and Optimization

In the pursuit of more efficient clinical trials, digital twin technology offers a transformative approach by significantly reducing costs and development time. By enabling the simulation of trials, digital twins help streamline the clinical trial process, ensuring faster and more cost-effective development of new therapies.

Digital twins allow researchers to create virtual models of patients, which can be used to simulate various aspects of clinical trials before initiating physical trials. This capability helps in identifying potential issues, optimizing trial designs, and predicting patient responses, thus reducing the need for extensive and expensive physical trials. The ability to test and refine protocols in a virtual environment leads to fewer amendments and protocol deviations, which are common sources of increased costs and delays in traditional trials.

Additionally, digital twins can enhance patient recruitment and retention by simulating different recruitment strategies and identifying the most effective approaches. By predicting which patients are most likely to benefit from a specific treatment, digital twins can help target recruitment efforts more precisely, reducing the time and resources spent on enrolling unsuitable candidates. This targeted approach not only accelerates the recruitment process but also improves the likelihood of trial success.

The real-time data analysis and monitoring capabilities of digital twins also contribute to cost and time savings. Continuous monitoring allows for the early detection of adverse events and other issues, enabling timely interventions that can prevent trial disruptions. This proactive management reduces the likelihood of costly trial delays and ensures that trials stay on track.

Furthermore, digital twins support adaptive trial designs, which allow for modifications to trial protocols based on interim results. This flexibility means that trials can be adjusted in real-time to reflect emerging data, improving their efficiency and effectiveness. Adaptive trials are often faster and less expensive than traditional fixed-design trials, as they make better use of available resources and data.

In summary, digital twin technology reduces the costs and time associated with clinical trials by enabling virtual simulations, optimizing patient recruitment, enhancing real-time monitoring, and supporting adaptive trial designs. These efficiencies lead to faster, more cost-effective development of new therapies, ultimately benefiting patients and healthcare providers by accelerating the availability of innovative treatments.

Efficient Trial Design

The ability to simulate trials using digital twins can significantly reduce the need for extensive physical trials, cutting down on both time and financial resources. By identifying issues early and making necessary adjustments, digital twins streamline the clinical trial process, leading to faster and more cost-effective development of new therapies.

Digital twins enable researchers to create virtual representations of clinical trials, allowing for the testing of various hypotheses and treatment protocols in a simulated environment. This virtual testing can reveal potential issues and inefficiencies before physical trials are conducted, enabling researchers to refine their approaches and focus on the most promising treatment options. As a result, the number of physical trials required can be significantly reduced, saving both time and money.

The predictive analytics capabilities of digital twins also play a crucial role in efficient trial design. By using real-time data and advanced modeling techniques, digital twins can forecast patient responses to treatments, identify potential adverse effects, and suggest optimal dosing regimens. This foresight allows researchers to design trials that are more likely to succeed, reducing the risk of costly trial failures and the need for repeated studies.

Furthermore, digital twins facilitate adaptive trial designs, where protocols can be modified in response to interim results. This adaptability ensures that clinical trials remain aligned with the evolving understanding of treatment efficacy and safety. For example, if a digital twin simulation indicates that a particular patient subgroup is responding exceptionally well to a treatment, the trial design can be adjusted to include more participants from that subgroup, enhancing the trial’s relevance and impact.

The efficiency gains from using digital twins extend to regulatory interactions as well. By providing comprehensive and robust data from simulated trials, researchers can present compelling evidence to regulatory bodies, potentially expediting the review and approval process. This streamlined regulatory pathway is particularly beneficial for innovative therapies and those targeting unmet medical needs, as it allows for quicker access to new treatments for patients.

In summary, the use of digital twins in efficient trial design significantly reduces the need for extensive physical trials, cutting down on time and financial resources. By identifying issues early and making necessary adjustments, digital twins streamline the clinical trial process, leading to faster and more cost-effective development of new therapies, ultimately facilitating quicker market access and improving patient care.

Improved Data Integration

Digital twins integrate data from various sources, such as electronic health records (EHRs), wearable devices, and genomic data, providing a comprehensive view of the patient’s health. This holistic approach enhances the accuracy of trial outcomes, ensuring that new treatments meet regulatory standards more efficiently and effectively.

The integration of diverse data sources into a single digital twin model allows for a more detailed and precise representation of a patient’s health status. By combining EHRs, which offer historical medical data, with real-time data from wearable devices and genetic information, digital twins create a comprehensive picture of a patient’s health trajectory. This extensive dataset enables researchers to understand better how various factors interact and influence patient outcomes.

This holistic approach is particularly valuable in clinical trials, where accurate and reliable data is crucial for assessing the efficacy and safety of new treatments. Digital twins can simulate how different patient profiles respond to treatments by leveraging integrated data, providing insights into potential outcomes that might not be evident through traditional trial methods. This comprehensive analysis helps in identifying the most effective treatment strategies and optimizing trial designs to target specific patient populations.

Furthermore, the use of integrated data enhances the ability to predict and monitor adverse effects. Digital twins can continuously analyze data from various sources, allowing for the early detection of potential safety concerns. This proactive monitoring ensures that necessary adjustments can be made promptly, improving patient safety and the reliability of trial results.

Regulatory agencies require robust and comprehensive evidence to approve new treatments. The holistic data provided by digital twins meets these stringent requirements more efficiently and effectively. By demonstrating a thorough understanding of treatment impacts across diverse patient populations, researchers can present compelling evidence to regulatory bodies, potentially accelerating the approval process.

In addition, the comprehensive data integration capabilities of digital twins support adaptive trial designs, where real-time data can guide modifications to trial protocols. This adaptability ensures that trials remain relevant and responsive to emerging insights, further enhancing their efficiency and effectiveness.

In summary, digital twins’ integration of data from EHRs, wearable devices, and genomic data provides a comprehensive view of the patient’s health, enhancing the accuracy of trial outcomes. This holistic approach ensures that new treatments meet regulatory standards more efficiently and effectively, facilitating quicker market access and ultimately benefiting patient care.

Digital Twins for Facilitating Regulatory Approval

Digital twins are revolutionizing the regulatory approval process for new treatments through advanced predictive modeling and comprehensive data-driven evidence. By simulating treatment scenarios and assessing potential risks, digital twins enable researchers and regulators to understand the impacts of new therapies more clearly. This predictive foresight supports informed decision-making, reduces uncertainties, and smooths the pathway to regulatory approval. Additionally, the integration of diverse data sources such as electronic health records, wearable devices, and genomic information provides robust evidence of treatment safety and efficacy. This data-rich approach enhances the credibility of submissions to regulatory bodies, increasing the likelihood of approval and accelerating market access for new therapies. Ultimately, digital twins not only streamline the approval process but also ensure that new treatments reach patients more quickly, thereby improving healthcare outcomes.

Predictive Modeling and Risk Assessment

Digital twins allow for advanced predictive modeling and risk assessment, helping researchers and regulators understand the potential impacts of new treatments. This foresight can lead to more informed decision-making, reducing uncertainties and facilitating a smoother regulatory approval process.

The ability to create detailed predictive models using digital twins enables researchers to simulate various treatment scenarios and assess potential risks before actual clinical trials begin. By analyzing these simulations, researchers can identify and address potential issues early in the development process, ensuring that only the safest and most effective treatments move forward. This proactive approach reduces the likelihood of encountering significant problems during physical trials, thereby smoothing the pathway to regulatory approval.

Furthermore, digital twins can model long-term outcomes and rare adverse effects that may not be apparent in shorter or smaller-scale trials. This comprehensive risk assessment provides regulators with a clearer understanding of a treatment’s potential impact, allowing for more informed and confident decision-making. By reducing uncertainties, digital twins facilitate a more streamlined and efficient regulatory review process.

Data-Driven Evidence

The rich data generated by digital twins provides robust evidence of a treatment’s safety and efficacy. This data-driven approach can strengthen submissions to regulatory bodies, increasing the likelihood of approval and speeding up the process of bringing new therapies to market.

Digital twins integrate data from multiple sources, including electronic health records, wearable devices, and genomic information, to create a comprehensive dataset. This extensive data collection allows for a thorough analysis of how treatments perform across diverse patient populations. By presenting detailed and data-driven evidence of a treatment’s effectiveness and safety, researchers can make a compelling case to regulatory bodies.

Moreover, digital twins enable continuous monitoring and real-time analysis throughout the clinical trial process. This ongoing data collection ensures that researchers can provide up-to-date and accurate information to regulators, addressing any concerns promptly. The ability to present comprehensive and dynamic evidence enhances the credibility of the submission, increasing the likelihood of regulatory approval.

The use of digital twins also supports adaptive trial designs, where real-time data can guide modifications to trial protocols. This flexibility ensures that trials remain aligned with the latest insights, further strengthening the evidence base for regulatory submissions. By demonstrating the ability to adapt and optimize trial designs based on real-time data, researchers can showcase the robustness of their approach to regulators.

In summary, digital twins facilitate regulatory approval through advanced predictive modeling and risk assessment, helping to reduce uncertainties and support informed decision-making. The rich, data-driven evidence generated by digital twins strengthens submissions to regulatory bodies, increasing the likelihood of approval and accelerating the process of bringing new therapies to market. This technology ensures that new treatments can reach patients more quickly, ultimately improving healthcare outcomes.

Ethical and Practical Considerations of Digital Twins

As digital twin technology becomes more integrated into healthcare and clinical trials, a number of ethical and practical considerations must be addressed to ensure its successful and responsible implementation. Paramount among these are data privacy and security, interoperability and integration, ethical concerns, cost and resource allocation, and technological limitations. Each of these aspects plays a critical role in maximizing the benefits of digital twins while maintaining trust, compliance, and efficacy within the healthcare industry.

Data Privacy and Security

Ensuring the confidentiality and security of patient data is paramount when utilizing digital twins. Implementing stringent data protection measures is essential to maintain trust and compliance with regulatory requirements. The integration of digital twins into healthcare and clinical trials involves the collection, storage, and analysis of vast amounts of sensitive patient information. To protect this data, robust encryption methods, secure access controls, and regular security audits are necessary. Additionally, compliance with data protection regulations such as GDPR, HIPAA, and other relevant laws is crucial. These measures not only protect patient privacy but also enhance the credibility and acceptance of digital twin technology in the healthcare industry.

Interoperability and Integration

For digital twins to be effective, they must seamlessly integrate with existing clinical trial management systems and health IT infrastructure. Achieving this interoperability is crucial for maximizing the benefits of digital twins in clinical trials. Interoperability ensures that digital twins can access and utilize data from various sources, including electronic health records (EHRs), laboratory information systems, and wearable devices. This integration facilitates real-time data exchange and comprehensive patient monitoring, enhancing the accuracy and efficiency of clinical trials. Standards such as HL7 FHIR (Fast Healthcare Interoperability Resources) play a key role in enabling interoperability, ensuring that digital twins can communicate effectively with other health IT systems. Additionally, collaboration between technology developers, healthcare providers, and regulatory bodies is essential to address interoperability challenges and create a cohesive digital health ecosystem.

Ethical Considerations

The ethical implications of using digital twins in healthcare and clinical trials must also be carefully considered. Informed consent is a fundamental ethical requirement, ensuring that patients are fully aware of how their data will be used and the potential risks and benefits involved. Transparent communication and education about digital twin technology can help build patient trust and acceptance. Moreover, addressing potential biases in data collection and analysis is critical to ensure fair and equitable treatment outcomes. Researchers must be vigilant in identifying and mitigating any sources of bias that could affect the accuracy and generalizability of trial results.

Cost and Resource Allocation

Implementing digital twin technology requires significant investment in infrastructure, training, and ongoing maintenance. The cost of developing and maintaining digital twins, as well as integrating them into existing systems, can be substantial. Therefore, careful consideration of the cost-benefit ratio is necessary to ensure that the adoption of digital twins is justified by the potential improvements in clinical trial efficiency and patient outcomes. Additionally, adequate training for healthcare professionals and researchers is essential to effectively utilize digital twin technology and interpret its outputs.

Technological Limitations and Challenges

While digital twins hold great promise, they are not without limitations and challenges. The accuracy and reliability of digital twin models depend on the quality and completeness of the underlying data. Incomplete or inaccurate data can lead to erroneous predictions and outcomes. Moreover, the complexity of human biology and the variability in patient responses pose challenges in creating precise and universally applicable digital twin models. Continuous research and development are needed to enhance the accuracy and applicability of digital twins, addressing these technological limitations and ensuring their effectiveness in clinical trials.

In summary, the ethical and practical considerations of using digital twins in clinical trials encompass data privacy and security, interoperability and integration, ethical concerns, cost and resource allocation, and technological limitations. Addressing these considerations is essential to maximize the benefits of digital twins, ensuring their successful implementation and acceptance in the healthcare industry.

Conclusion

Digital twins have the potential to revolutionize clinical trials by enhancing efficiency, reducing costs, and facilitating regulatory approval. This technology enables continuous patient monitoring, personalized treatment plans, and predictive simulations, which streamline trial protocols and improve outcomes. By integrating data from various sources, digital twins provide a comprehensive view of patient health, supporting accurate and reliable trial results.

They also address ethical and practical considerations such as data privacy, security, and interoperability. As digital twins become more advanced, they promise significant advancements in personalized medicine and overall healthcare delivery, ultimately accelerating the development and approval of new treatments and improving global health outcomes.

Guvenc Kockaya, June 2024

FAQ: The Possible Impact of Digital Twins on Market Access Through Clinical Trials

1. What are digital twins in clinical trials? Digital twins are precise virtual models of individual patients created using real-time data. These models simulate different scenarios, predict outcomes, and provide personalized treatment plans, enhancing the clinical trial process and potentially improving market access for new treatments.
2. How do digital twins improve patient recruitment and retention in clinical trials? Digital twins can simulate patient responses to treatments, helping researchers identify the most suitable candidates for trials. This reduces recruitment time and costs and improves patient adherence and retention by monitoring patient responses in real-time, thus providing more reliable data for market access submissions.
3. In what ways do digital twins facilitate the regulatory approval process? By providing robust and comprehensive evidence of a treatment’s efficacy and safety through simulations and predictive modeling, digital twins address regulatory concerns more effectively. This can accelerate the approval process, enhancing market access for new therapies by meeting regulatory requirements more efficiently.
4. What is the role of predictive modeling in digital twins? Predictive modeling in digital twins forecasts patient responses to treatments, identifies potential adverse effects, and suggests optimal dosing regimens. This helps design more successful and cost-effective trials, which can lead to quicker regulatory approval and market access.
5. How do digital twins contribute to cost and time savings in clinical trials? Digital twins enable virtual simulations of clinical trials, identifying potential issues and optimizing trial designs before physical trials begin. This reduces the need for extensive physical trials, lowering costs, speeding up the development process, and accelerating market access for new treatments.
6. What data sources do digital twins integrate for clinical trials? Digital twins integrate data from various sources such as electronic health records (EHRs), wearable devices, and genetic information. This comprehensive data aggregation allows for accurate and detailed patient monitoring and outcome prediction, which can support market access strategies by providing extensive evidence of treatment benefits.
7. How do digital twins ensure data privacy and security? Ensuring data privacy and security is paramount when using digital twins. Robust encryption methods, secure access controls, and regular security audits are necessary to protect patient data. Compliance with regulations like GDPR and HIPAA is also crucial, maintaining trust and meeting regulatory standards required for market access.
8. What are the ethical considerations associated with digital twins in clinical trials? Ethical considerations include obtaining informed consent, ensuring transparent communication about how patient data will be used, and addressing potential biases in data collection and analysis to ensure fair and equitable treatment outcomes. These considerations are important for maintaining ethical standards and supporting market access by demonstrating responsible use of technology.
9. How do digital twins support personalized medicine? Digital twins advance personalized medicine by simulating how individual patients might respond to different treatment options based on their unique genetic makeup and health history. This enables healthcare providers to tailor therapies for each patient, improving treatment effectiveness and outcomes, and providing strong evidence for market access submissions.
10. What challenges and limitations do digital twins face in clinical trials? Challenges include ensuring the accuracy and reliability of digital twin models, which depend on the quality and completeness of the underlying data. Additionally, the complexity of human biology and variability in patient responses pose challenges in creating precise and universally applicable digital twin models. Continuous research and development are needed to address these limitations, ensuring that digital twins can effectively support clinical trials and market access strategies.

References

• Das, T., Wang, Z., & Sun, J. (2023). TWIN: Personalized Clinical Trial Digital Twin Generation. Proceedings of the 29th ACM SIGKDD Conference on Knowledge Discovery and Data Mining.
• Susilo, M., Li, C., Gadkar, K., Hernandez, G., Huw, L., Jin, J., Yin, S., Wei, M., Ramanujan, S., & Hosseini, I. (2023). Systems‐based digital twins to help characterize clinical dose–response and propose predictive biomarkers in a Phase I study of bispecific antibody, mosunetuzumab, in NHL. Clinical and Translational Science, 16, 1134-1148.
• Jensen, J., & Deng, J. (2023). Digital Twins for Radiation Oncology. Companion Proceedings of the ACM Web Conference 2023.
• Bordukova, M., Makarov, N., Rodriguez-Esteban, R., Schmich, F., & Menden, M. P. (2023). Generative artificial intelligence empowers digital twins in drug discovery and clinical trials. Expert Opinion on Drug Discovery, 1-10.
• Wu, C., Lorenzo, G., Hormuth, D., Lima, E., Slavkova, K. P., DiCarlo, J., Virostko, J., Phillips, C. M., Patt, D., Chung, C., & Yankeelov, T. (2022). Integrating mechanism-based modeling with biomedical imaging to build practical digital twins for clinical oncology. Biophysics Reviews, 3(2), 021304.
• Stahlberg, E. A., Abdel-Rahman, M., Aguilar, B., Asadpoure, A., Beckman, R., Borkon, L. L., Bryan, J. C., Cebulla, C., Chang, Y., Chatterjee, A., Deng, J., Dolatshahi, S., Gevaert, O., Greenspan, E., Hao, W., Hernandez-Boussard, T., Jackson, P., Kuijjer, M., Lee, A., Macklin, P., Madhavan, S., McCoy, M., Mirzaei, N. M., Razzaghi, T., Rocha, H., Shahriyari, L., Shmulevich, I., Stover, D., Sun, Y., Syeda-Mahmood, T., Wang, J., & Zervantonakis, I. (2022). Exploring approaches for predictive cancer patient digital twins: Opportunities for collaboration and innovation. Frontiers in Digital Health, 4.
• Filippo, M. D., Damiani, C., Vanoni, M., Maspero, D., Mauri, G., Alberghina, L., & Pescini, D. (2020). Single-cell Digital Twins for Cancer Preclinical Investigation. Methods in Molecular Biology, 2088, 331-343.
• Allen, A., Siefkas, A., Pellegrini, E., Burdick, H., Barnes, G., Calvert, J., Mao, Q., & Das, R. (2021). A Digital Twins Machine Learning Model for Forecasting Disease Progression in Stroke Patients. Applied Sciences, 11, 5576.
• Rahmim, A., Brosch-Lenz, J., Fele-Paranj, A., Yousefirizi, F., Soltani, M., Uribe, C., & Saboury, B. (2022). Theranostic digital twins for personalized radiopharmaceutical therapies: Reimagining theranostics via computational nuclear oncology. Frontiers in Oncology, 12.
• Kaul, R., Ossai, C. I., Forkan, A., Jayaraman, P., Zelcer, J., Vaughan, S., & Wickramasinghe, N. (2022). The role of AI for developing digital twins in healthcare: The case of cancer care. Wiley Interdisciplinary Reviews: Data Mining and Knowledge Discovery, 13.

Guvenc Kockaya